BACKGROUND: A clinical pilot study performed by our group showed that dacarbazine can induce a marked reduction of blast cells in patients with acute myelogenous leukaemia (AML). Leukaemic blasts (LB) from responsive patients showed low levels of O6-alkylguanine-DNA alkyltransferase (OGAT). DESIGN: An in vitro study was performed to evaluate OGAT levels and sensitivity to temozolomide (a triazene compound that spontaneously decomposes into the active metabolite of dacarbazine) in a relatively large number of LB samples. RESULTS: OGAT levels varied widely among the LB of different patients, with a mean value higher in acute lymphoblastic leukaemias than in AML. About 25% of LB obtained from patients with AML showed low OGAT activity, in the range corresponding to that observed in leukaemic patients responsive to dacarbazine in vivo. A reasonable inverse correlation was found between OGAT levels and LB sensitivity to temozolomide. CONCLUSIONS: Triazenes could have a therapeutic potential in human leukaemias. Moreover, OGAT determination could provide rapid and reliable information about a patient's susceptibility to these antitumor agents.
BACKGROUND: A clinical pilot study performed by our group showed that dacarbazine can induce a marked reduction of blast cells in patients with acute myelogenous leukaemia (AML). Leukaemic blasts (LB) from responsive patients showed low levels of O6-alkylguanine-DNA alkyltransferase (OGAT). DESIGN: An in vitro study was performed to evaluate OGAT levels and sensitivity to temozolomide (a triazene compound that spontaneously decomposes into the active metabolite of dacarbazine) in a relatively large number of LB samples. RESULTS: OGAT levels varied widely among the LB of different patients, with a mean value higher in acute lymphoblastic leukaemias than in AML. About 25% of LB obtained from patients with AML showed low OGAT activity, in the range corresponding to that observed in leukaemic patients responsive to dacarbazine in vivo. A reasonable inverse correlation was found between OGAT levels and LB sensitivity to temozolomide. CONCLUSIONS:Triazenes could have a therapeutic potential in humanleukaemias. Moreover, OGAT determination could provide rapid and reliable information about a patient's susceptibility to these antitumor agents.
Authors: Stephen T Keir; John M Maris; C Patrick Reynolds; Min H Kang; E Anders Kolb; Richard Gorlick; Richard Lock; Hernan Carol; Christopher L Morton; Jianrong Wu; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2013-01-17 Impact factor: 3.167
Authors: Terzah M Horton; Patrick A Thompson; Stacey L Berg; Peter C Adamson; Ashish M Ingle; M Eileen Dolan; Shannon M Delaney; Madhuri Hedge; Heidi L Weiss; Meng-Fen Wu; Susan M Blaney Journal: J Clin Oncol Date: 2007-11-01 Impact factor: 44.544
Authors: Yuichi Hirose; Makoto Katayama; David Stokoe; Daphne A Haas-Kogan; Mitchel S Berger; Russell O Pieper Journal: Mol Cell Biol Date: 2003-11 Impact factor: 4.272
Authors: M Brada; I Judson; P Beale; S Moore; P Reidenberg; P Statkevich; M Dugan; V Batra; D Cutler Journal: Br J Cancer Date: 1999-11 Impact factor: 7.640
Authors: B Geoerger; G Vassal; F Doz; J O'Quigley; M Wartelle; A J Watson; M-A Raquin; D Frappaz; P Chastagner; J-C Gentet; H Rubie; D Couanet; A Geoffray; L Djafari; G P Margison; F Pein Journal: Br J Cancer Date: 2005-09-05 Impact factor: 7.640
Authors: Patricia de Maria Silva Figueirêdo; José Costa Sampaio Filho; Alzirene de Jesus Sales Sodré; José Ribamar de Castro Júnior; Ingrid Santos Gonçalves; Rodrigo Vieira Blasques; Rodrigo S Correa; Benedicto Augusto Vieira Lima; Larissa Dos Anjos Marques; Denise Fernandes Coutinho; Ana Paula Silva de Azevedo Dos Santos; Tássio Rômulo Silva Araújo Luz; Rita de Cassia Mendonça de Miranda; Julliana Ribeiro Alves Dos Santos; Antonio Carlos Doriguetto; María Isabel Pividori; Manfredo Hörner; Paulo Cesar Mendes Villis Journal: Sci Rep Date: 2021-01-28 Impact factor: 4.379
Authors: O A Khan; M Ranson; M Michael; I Olver; N C Levitt; P Mortimer; A J Watson; G P Margison; R Midgley; M R Middleton Journal: Br J Cancer Date: 2008-05-13 Impact factor: 7.640